Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

PD-L1 anticorps (AA 39-191)

PD-L1 Reactivité: Humain WB, FACS, ELISA, IF, Coat, IHC (f) Hôte: Souris Monoclonal PDL1-2746 unconjugated
N° du produit ABIN6936656
  • Antigène Voir toutes PD-L1 Anticorps
    PD-L1 (CD274 (PD-L1))
    Épitope
    • 29
    • 16
    • 15
    • 13
    • 11
    • 10
    • 9
    • 7
    • 7
    • 5
    • 4
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    AA 39-191
    Reactivité
    • 170
    • 108
    • 63
    • 7
    • 6
    • 5
    • 5
    • 1
    • 1
    Humain
    Hôte
    • 127
    • 61
    • 17
    • 4
    • 4
    • 1
    Souris
    Clonalité
    • 108
    • 104
    • 2
    Monoclonal
    Conjugué
    • 98
    • 16
    • 13
    • 11
    • 9
    • 5
    • 5
    • 5
    • 5
    • 5
    • 5
    • 5
    • 4
    • 4
    • 4
    • 4
    • 4
    • 4
    • 3
    • 2
    • 1
    • 1
    • 1
    Cet anticorp PD-L1 est non-conjugé
    Application
    • 138
    • 103
    • 59
    • 40
    • 38
    • 28
    • 17
    • 17
    • 16
    • 14
    • 10
    • 6
    • 5
    • 5
    • 3
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Western Blotting (WB), Flow Cytometry (FACS), ELISA, Immunofluorescence (IF), Coating (Coat), Immunohistochemistry (Formalin-fixed Sections) (IHC (f))
    Specificité
    PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system.
    Réactivité croisée (Details)
    Human. Mouse.
    Purification
    1.0mg/ml of Ab purified from Bioreactor by Protein A/G.
    Immunogène
    Recombinant fragment (around aa 39-191) of human CD274 (PD-L1) protein (exact sequence is proprietary)
    Clone
    PDL1-2746
    Isotype
    IgG2b kappa
    Top Product
    Discover our top product PD-L1 Anticorps primaire
  • Indications d'application

    Known_Application: ELISA (For coating, order antibody without BSA), Western Blot (1-2 μg/mL),Flow Cytometry (1-2 μg/million cells), Immunofluorescence (1-2 μg/mL),Immunohistochemistry (Formalin-fixed) (1-2 μg/mL for 30 minutes at RT),(Staining of formalin-fixed tissues requires heating tissue sections in 10 mM Tris with 1 mM EDTA, pH 9.0, for 45 min at 95°C followed by cooling at RT for 20 minutes), Optimal dilution for a specific application should be determined.

    Positive_Control: Heart, Placenta, Spleen or Tonsil tissue. RAW, MDA-MB-231 or HepG2 cell lysates. Jurkat cells.

    Restrictions
    For Research Use only
  • Concentration
    1.0 mg/mL
    Buffer
    Prepared in 10 mM PBS, WITHOUT BSA and Azide.
    Agent conservateur
    Azide free
    Stock
    -20 °C,-80 °C
    Stockage commentaire
    Antibody without azide store at -20 to -80 °C. Antibody is stable for 24 months. Non-hazardous.
    Date de péremption
    24 months
  • Antigène
    PD-L1 (CD274 (PD-L1))
    Autre désignation
    CD274 (PD-L1 Produits)
    Synonymes
    anticorps B7-H, anticorps B7H1, anticorps PD-L1, anticorps PDCD1L1, anticorps PDCD1LG1, anticorps PDL1, anticorps A530045L16Rik, anticorps B7h1, anticorps Pdcd1l1, anticorps Pdcd1lg1, anticorps Pdl1, anticorps RGD1566211, anticorps CD274 molecule, anticorps CD274 antigen, anticorps programmed cell death 1 ligand 2, anticorps CD274, anticorps Cd274, anticorps PDCD1LG2
    Sujet
    B7 homolog 1, B7-H1, CD274, PD-L1, PDCD1 ligand 1, PDCD1L1, PDCD1LG1, Programmed cell death 1 ligand 1,PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target)
    Cellular localisation: Cell Surface and Cytoplasmic
    Poids moléculaire
    37-50kDa
    ID gène
    29126, 521989
    UniProt
    Q9NZQ7
    Pathways
    Cancer Immune Checkpoints
Vous êtes ici:
Support technique